Oncology is a key therapeutic area for AbbVie, with a portfolio consisting of three marketed products — Imbruvica, Venclexta, and Empliciti — and a pipeline containing multiple promising new molecules that are being studied in nearly 200 clinical trials in 19 different types of cancer. AbbVie is expanding its oncology hub on the West Coast, with three sites in the San Francisco Bay Area (Redwood City, South San Francisco, and Sunnyvale) focused on the discovery and development of novel oncology therapies. More than 1,000 AbbVie scientists, clinicians, and product developers with strong entrepreneurial roots work across these three sites. They combine their expertise in immuno-oncology, stem cells, and cell-signaling with their knowledge of bispecific antibodies, antibody-drug conjugates (ADCs), and covalent-inhibitor technologies to discover and develop novel cancer treatments. This position is based at Stemcentrx, AbbVie’s South San Francisco, CA location.
AbbVie Stemcentrx is embracing new paradigms and technologies to develop novel and life-changing therapies for cancer. As part of a talented and multi-disciplinary team advancing an exciting approach to drug development, we are seeking a highly motivated candidate to join our process science team. The primary responsibility of this role is to develop, optimize and perform analytical methods to characterize toxins and linker-drugs for antibody drug conjugates. This role will work closely with Discovery Chemistry, DMPK and Bioconjugation teams for novel linker-drugs development. The opportunity will provide exposure to the candidate on various facets of research, process development for novel linker-drugs and ADC technologies, and multiple state of the art MS instruments and analytical workflows.